---
document_datetime: 2023-09-21 20:07:11
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/duzallo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: duzallo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.4253005
conversion_datetime: 2025-12-24 15:20:06.275978
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended no   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10704 /201912  | Periodic Safety Update EU Single assessment - allopurinol / lesinurad                                        | 09/07/2020                          | n/a                                         | PRAC Recommendation -            | maintenance                       |
| PSUSA/10704 /201906  | Periodic Safety Update EU Single assessment - allopurinol / lesinurad product                                | 16/01/2020                          | on n/a                                      |                                  | PRAC Recommendation - maintenance |
| IB/0003              | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a | 26/08/2019                          | n/a                                         |                                  |                                   |

Official address

●

Domenico Scarlattilaan 6

1083 HS Amsterdam

●

The Netherlands

Refer to www.ema.europa.eu/how-to-find-us

<!-- image -->

An agency of the European Union Address for visits and deliveries Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 Duzallo Procedural steps taken and scientific information after the authorisation 1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures. 2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). edicinal product no longer authorise

<div style=\"page-break-after: always\"></div>

|                     | re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                 |            |                        |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|-----------------------------------|
| IB/0002/G           | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 31/07/2019 | SmPC, Labelling and PL | longer                            |
| PSUSA/10704 /201812 | Periodic Safety Update EU Single assessment - allopurinol / lesinurad                                                                                                                                                                                                                                                                                                                                                                                     | 11/04/2019 | n/a no                 | PRAC Recommendation - maintenance |

<!-- image -->